Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00913081 · ClinicalTrials.gov registry record · Phase 4
Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)
A Phase 4 study of Flushing, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT00913081 is a Phase 4 study of Flushing that has completed, run by University of Pennsylvania. The registered enrollment target is 17 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT00913081, a Phase 4 study of Flushing, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
Niacin, or vitamin B3, is known to improve cholesterol disorders and is the most effective drug to raise HDL, or the "good cholesterol". The use of niacin has been limited because of a peculiar adverse effect referred to as "flushing', which consists of redness, warmth, tingling and burning. A recent animal study suggests that flavonoids may prevent flushing due to niacin better than drugs like aspirin. The ANTI-FLUSH study is being done to assess whether a presently available dietary supplement known as quercetin, which is a flavonoid, can reduce the flushing that occurs with niacin. We will also assess whether using quercetin to prevent flushing from niacin, can improve how niacin lowers cholesterol.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Quercetin
Study Locations (2)
Pennsylvania
- CTRC Univ. of Penn - Andrew Mutch Bldg., 4th floor - Philadelphia
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00913081
The ClinicalTrials.gov registry entry for NCT00913081 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Flushing appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00913081 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00913081 about?
NCT00913081 is a clinical study titled "Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)". Niacin, or vitamin B3, is known to improve cholesterol disorders and is the most effective drug to raise HDL, or the "good cholesterol". The use of niacin has been limited because of a peculiar adverse effect referred to as "flushing', which consists of redness, warmth, tingling and burning. A recen...
What is the current status of trial NCT00913081?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2009-02. Estimated completion is 2009-12.
What conditions does trial NCT00913081 study?
This clinical trial studies the following conditions: Flushing.
What interventions are being tested in trial NCT00913081?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Quercetin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00913081?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00913081 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Flushing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.